292 related articles for article (PubMed ID: 18599033)
1. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
Gunnet JW; Wines P; Xiang M; Rybczynski P; Andrade-Gordon P; de Garavilla L; Parry TJ; Cheung WM; Minor L; Demarest KT; Maryanoff BE; Damiano BP
Eur J Pharmacol; 2008 Aug; 590(1-3):333-42. PubMed ID: 18599033
[TBL] [Abstract][Full Text] [Related]
2. Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.
Gunnet JW; Matthews JM; Maryanoff BE; de Garavilla L; Andrade-Gordon P; Damiano B; Hageman W; Look R; Stahle P; Streeter AJ; Wines PG; Demarest KT
Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):320-6. PubMed ID: 16620295
[TBL] [Abstract][Full Text] [Related]
3. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
4. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
Nakamura S; Yamamura Y; Itoh S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Ogawa H; Shinohara T; Kan K; Tanada Y; Teramoto S; Sumida T; Nakayama S; Sekiguchi K; Kambe T; Tsujimoto G; Mori T; Tominaga M
Br J Pharmacol; 2000 Apr; 129(8):1700-6. PubMed ID: 10780976
[TBL] [Abstract][Full Text] [Related]
6. Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.
Xiang MA; Rybczynski PJ; Patel M; Chen RH; McComsey DF; Zhang HC; Gunnet JW; Look R; Wang Y; Minor LK; Zhong HM; Villani FJ; Demarest KT; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2007 Dec; 17(23):6623-8. PubMed ID: 17942308
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V(1A) receptor antagonist 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245).
Russell R; Doyle R; Turner J; Attkins N; Ramsey S; Weibley L; Bateman L; Bictash M; Neal-Morgan S; Ivarsson M; Pullen N
Eur J Pharmacol; 2011 Nov; 670(2-3):347-55. PubMed ID: 21958878
[TBL] [Abstract][Full Text] [Related]
8. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
Laporte R; Kohan A; Heitzmann J; Wisniewska H; Toy J; La E; Tariga H; Alagarsamy S; Ly B; Dykert J; Qi S; Wisniewski K; Galyean R; Croston G; Schteingart CD; Rivière PJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):786-96. PubMed ID: 21411496
[TBL] [Abstract][Full Text] [Related]
10. Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.
Tahara A; Tsukada J; Tomura Y; Suzuki T; Yatsu T; Shibasaki M
Vascul Pharmacol; 2007 Jun; 46(6):463-9. PubMed ID: 17395547
[TBL] [Abstract][Full Text] [Related]
11. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.
Tahara A; Tomura Y; Wada KI; Kusayama T; Tsukada J; Takanashi M; Yatsu T; Uchida W; Tanaka A
J Pharmacol Exp Ther; 1997 Jul; 282(1):301-8. PubMed ID: 9223568
[TBL] [Abstract][Full Text] [Related]
13. Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
Tsukada J; Tahara A; Tomura Y; Wada Ki ; Kusayama T; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Br J Pharmacol; 2001 Jul; 133(5):746-54. PubMed ID: 11429400
[TBL] [Abstract][Full Text] [Related]
14. Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells.
Tahara A; Tsukada J; Tomura Y; Momose K; Suzuki T; Yatsu T; Shibasaki M
Eur J Pharmacol; 2006 May; 538(1-3):32-8. PubMed ID: 16678155
[TBL] [Abstract][Full Text] [Related]
15. Age-dependent regulation of renal vasopressin V(1A) and V₂ receptors in rats with genetic hypertension: implications for the treatment of hypertension.
Burrell LM; Risvanis J; Dean RG; Patel SK; Velkoska E; Johnston CI
J Am Soc Hypertens; 2013; 7(1):3-13. PubMed ID: 23246465
[TBL] [Abstract][Full Text] [Related]
16. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin and angiotensin receptors of the medial septal area in the control of mean arterial pressure induced by vasopressin.
Pavan de Arruda Camargo GM; Abrão Saad W; de Arruda Camargo LA
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):133-8. PubMed ID: 18957383
[TBL] [Abstract][Full Text] [Related]
18. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent regulation of vasopressin V1a receptors in preglomerular vessels from the spontaneously hypertensive rat.
Vågnes B ØB; Hansen FH; Christiansen RE; Gjerstad C; Iversen BM
Am J Physiol Renal Physiol; 2004 May; 286(5):F997-1003. PubMed ID: 15075196
[TBL] [Abstract][Full Text] [Related]
20. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
